

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of the groups n = 5

EQA round: AP2/20 - Antithrombotic Agents

Deadline: 18.09.2020

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 1														
(108) Apixaban					30							30	29	97%
Samples and groups		[µg/L]												
Sample A1		207	21	10	30	CVP	207	9,4	25%	155	259	30	30	100%
(38) IL		224	14	6,2	8	0						8		
(63) Sysmex		194	20	10	11	0						11		
(94) Stago		203	9,6	4,8	7	0						7		
Other					4	0						4		
							3x 149, 1x 179							
Sample B1		406	27	6,5	30	CVP	406	12	25%	304	508	30	29	97%
(38) IL		429	14	3,3	8	0						8		
(63) Sysmex		398	24	5,9	11	0						11		
(94) Stago		405	18	4,4	7	0						7		
Other					4	0						4		
							3x 149, 1x 179							
Set 2														
(109) Dabigatran					33							33	30	91%
Samples and groups		[µg/L]												
Sample A2		103	16	16	33	CVP	103	6,9	25%	77,2	129	33	30	91%
(38) IL		103	12	12	11	0						11		
(63) Sysmex		103	20	19	12	0						12		
(94) Stago		113	12	10	6	0						6		
Other					4	0						4		
							3x 149, 1x 179							
Sample B2		295	32	11	33	CVP	295	14	25%	221	369	33	33	100%
(38) IL		292	29	10	11	0						11		
(63) Sysmex		292	33	11	12	0						12		
(94) Stago		316	32	10	6	0						6		
Other					4	0						4		
							3x 149, 1x 179							
Set 3														
(110) Rivaroxaban					36							36	36	100%
Samples and groups		[µg/L]												
Sample A3		95,5	12	13	36	CVP	95,5	5,1	25%	71,6	120	36	36	100%
(38) IL		95,7	8,2	8,6	10	0						10		
(63) Sysmex		96,8	12	13	14	0						14		
(94) Stago		81,5	6,7	8,2	7	0						7		
Other					5	0						5		
							4x 149, 1x 179							
Sample B3		283	28	9,9	36	CVP	283	11	25%	212	354	36	36	100%
(38) IL		254	9,9	3,9	10	0						10		
(63) Sysmex		301	16	5,3	14	0						14		
(94) Stago		276	14	5,1	7	0						7		
Other					5	0						5		
							4x 149, 1x 179							

st_kn_p

End of report

Printed: 24.09.2020